This technology is a therapeutic targeting neurodegenerative disorders involving small molecules to enhance lipid and cholesterol metabolism in the brain via activation of lecithin cholesterol acyltransferase (LCAT).
Current methods to treat neurodegenerative diseases such as Alzheimer’s disease (AD) mainly involve the treatment of symptoms rather than addressing the underlying pathogenesis. The primary focus for developing AD therapeutics has currently been based on targeting biogenesis or clearance of amyloid plaques, but many of these clinical trials have resulted in failed efficacy tests. As a result, there is a need to develop therapeutics to treat and disrupt Alzheimer’s disease progression.
This technology describes a therapeutic to regulate lipid dyshomeostasis to treat Alzheimer’s disease and related disorders. This technology enhances lipid and cholesterol metabolism in the brain via activation of lecithin cholesterol acyltransferase (LCAT). Because dysregulation of lipid and cholesterol metabolism has been implicated in several neurodegenerative diseases, modification of lipid metabolism to enhance the function of lipid processing enzymes may be a potential therapeutic strategy for several neurodegenerative diseases.
This technology has been validated in vivo with an Alzheimer’s disease mouse model.
Patent Pending(WO/2023/122185)
IR CU20145, CU21112, CU22017
Licensing Contact: Jerry Kokoshka